New Triple-Threat attack on HPV-Linked throat cancer enters testing
NCT ID NCT04369937
Summary
This study is testing whether adding a vaccine that targets the HPV virus to standard cancer treatments (chemotherapy, radiation, and an immunotherapy drug) can better control a specific type of throat cancer. It is for adults newly diagnosed with intermediate-risk, HPV-16 positive head and neck cancer that hasn't spread. The main goal is to see if this combination helps patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.